Allergology International

Allergology International

Volume 71, Issue 4, October 2022, Pages 448-458
Allergology International

Invited Review Article
Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021,

https://doi.org/10.1016/j.alit.2022.06.009Get rights and content
Under a Creative Commons license
open access

Abstract

This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. In Japan, from the perspective of evidence-based medicine, the current strategies for the treatment of AD consist of three primary measures: (i) use of topical corticosteroids, tacrolimus ointment, and delgocitinib ointment as the main treatment of the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling, and advice about daily life. In the present revised guidelines, the description about three new drugs, namely, dupilumab, delgocitinib, and baricitinib, has been added. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Keywords

Atopic dermatitis
Clinical practice guidelines
Clinical questions
Evidence-based medicine
Treatment

Cited by (0)

This is an abridged edition of “English version of clinical practice guidelines for the management of atopic dermatitis 2021.” By Saeki H et al. in J Dermatol 2022 (https://doi.org/10.1111/1346-8138.16527).

Peer review under responsibility of Japanese Society of Allergology.

1

Hidehisa Saeki is the Chairperson, and Yukihiro Ohya and Junichi Furuta are the Vice Chairpersons of the Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021.